NLRP3 and colorectal carcinoma: A growing body of evidence indicates that excessive pyroptosis of M1-type TAMs accelerates CRC progression [12, 13]; thus, the “NLRP3-caspase-1-IL-1β/IL-18” pathway has become a potential therapeutic target.